A detailed history of Exodus Point Capital Management, LP transactions in Ardelyx, Inc. stock. As of the latest transaction made, Exodus Point Capital Management, LP holds 921,711 shares of ARDX stock, worth $4.58 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
921,711
Previous 302,154 205.05%
Holding current value
$4.58 Million
Previous $2.24 Million 183.65%
% of portfolio
0.04%
Previous 0.02%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$5.28 - $7.57 $3.27 Million - $4.69 Million
619,557 Added 205.05%
921,711 $6.35 Million
Q2 2024

Aug 13, 2024

BUY
$5.89 - $9.31 $1.78 Million - $2.81 Million
302,154 New
302,154 $2.24 Million
Q3 2023

Nov 09, 2023

SELL
$3.3 - $4.83 $349,793 - $511,970
-105,998 Reduced 72.1%
41,016 $167,000
Q2 2023

Aug 10, 2023

BUY
$3.23 - $4.95 $474,855 - $727,719
147,014 New
147,014 $498,000
Q3 2022

Nov 10, 2022

BUY
$0.59 - $1.44 $133,470 - $325,758
226,221 New
226,221 $269,000
Q1 2022

May 13, 2022

SELL
$0.65 - $1.18 $25,438 - $46,180
-39,136 Closed
0 $0
Q4 2021

Feb 11, 2022

SELL
$0.86 - $1.7 $134,994 - $266,849
-156,970 Reduced 80.04%
39,136 $43,000
Q3 2021

Nov 15, 2021

BUY
$1.27 - $8.17 $249,054 - $1.6 Million
196,106 New
196,106 $259,000
Q1 2021

May 17, 2021

SELL
$6.1 - $7.69 $207,900 - $262,090
-34,082 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$5.05 - $7.1 $172,114 - $241,982
34,082 New
34,082 $221,000
Q3 2020

Nov 16, 2020

SELL
$5.25 - $7.08 $64,144 - $86,503
-12,218 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$5.37 - $8.11 $65,610 - $99,087
12,218 New
12,218 $85,000

Others Institutions Holding ARDX

About ARDELYX, INC.


  • Ticker ARDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 154,636,000
  • Market Cap $769M
  • Description
  • Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel synd...
More about ARDX
Track This Portfolio

Track Exodus Point Capital Management, LP Portfolio

Follow Exodus Point Capital Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Exodus Point Capital Management, LP with notifications on news.